The Graves’ ophthalmopathy market is expected to witness steady growth over the coming years, driven by the rising prevalence of autoimmune thyroid disorders, improved disease awareness, and earlier diagnosis. Additionally, the recent approval of LUMVOA has heightened competition in the Graves’ ophthalmopathy market. Furthermore, the expected approval of emerging therapies such as Elegrobart (Viridian Therapeutics), Linsitinib (Sling Therapeutics), AMG 732 (Amgen), and others, will further boost the market growth.

LAS VEGAS, July 29, 2026 /PRNewswire/ — Recently published Graves Ophthalmopathy Market Insights report includes a comprehensive understanding of current treatment practices, Graves ophthalmopathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Graves Ophthalmopathy Market Summary

• The market size for Graves ophthalmopathy was found to be USD 3.5 billion in the 7MM in 2025.
• The United States accounted for the largest Graves ophthalmopathy treatment market size of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2025, the total prevalent cases of Graves’ ophthalmopathy in the 7MM were ~2.4 million.
• Leading Graves ophthalmopathy companies, such as Viridian Therapeutics, Sling Therapeutics, Amgen, Alumis, Roche, and others, are developing new Graves ophthalmopathy treatment drugs that can be available in the Graves ophthalmopathy market in the coming years. 
• The promising Graves ophthalmopathy therapies in clinical trials include Elegrobart (VRDN-003), Linsitinib, AMG 732, Lonigutamab, ENSPRYNG (satralizumab, RG6168), and others.

Discover which companies are leading innovation or research in thyroid eye disease treatment, and how are they differentiated? @ https://www.delveinsight.com/report-store/graves-ophthalmopathy-market

Key Factors Driving the Growth of the Graves Ophthalmopathy Market 

• Rising Prevalence of Graves’ Disease and Thyroid Eye Disease: The increasing incidence of autoimmune thyroid disorders, particularly Graves’ disease, is expanding the patient pool at risk of developing Graves’ ophthalmopathy. Improved diagnosis and longer patient survival are further contributing to market growth.
• Advances in Precision Medicine and Personalized Treatment: Improved understanding of the immunological mechanisms underlying Graves’ ophthalmopathy is enabling the development of targeted treatment strategies. Personalized approaches are expected to enhance efficacy while reducing treatment-related adverse effects.
• Entry of Viridian’s LUMVOA: The recent approval of LUMVOA has further intensified the competition in the Graves ophthalmopathy market. As the first approved therapy with clinical labeling covering both active and chronic TED, LUMVOA expands the addressable patient population beyond currently treated active cases.
• Rise in Clinical Trial Activities: The dynamics of the Graves ophthalmopathy market are expected to change in the coming years, owing to the launch of emerging therapies such as Elegrobart (VRDN-003) (Viridian Therapeutics), Linsitinib (Sling Therapeutics), AMG 732 (Amgen), Lonigutamab (Alumis), ENSPRYNG (satralizumab, RG6168) (Roche), and others.

According to Aparna Thakur, Project Manager of Forecasting at DelveInsight, among approved therapies, TEPEZZA is expected to remain the leading revenue contributor due to its proven efficacy in reducing proptosis and its status as the only disease-specific approved treatment for Graves’ ophthalmopathy. However, the anticipated entry of late- to mid-stage pipeline candidates, including elegrobart (VRDN-003), satralizumab (RG6168), and linsitinib, is expected to intensify market competition and drive a transition toward more convenient subcutaneous and oral targeted therapies throughout the forecast period.

Graves Ophthalmopathy Market Analysis

• The treatment paradigm for Graves’ ophthalmopathy has evolved considerably, moving beyond symptomatic management and surgical intervention toward targeted immunomodulatory therapies. 
• Standard treatment for active disease primarily involves high-dose intravenous corticosteroids, including methylprednisolone. For patients with an inadequate response to conventional therapy, off-label biologic agents such as Tocilizumab and Rituximab are frequently considered, despite lacking specific regulatory approval for thyroid eye disease.
• A major advancement in the field was the approval of Teprotumumab (TEPEZZA) by Amgen, the first targeted therapy specifically indicated for TED. By inhibiting the insulin-like growth factor-1 receptor (IGF-1R), Teprotumumab has demonstrated significant improvements in proptosis and diplopia, transforming the treatment landscape.
• Further progress was achieved in June 2026, when the FDA approved LUMVOA (veligrotug-vvze), developed by Viridian Therapeutics, for the treatment of thyroid eye disease. 
• The approval was granted under the FDA’s Priority Review program and was supported by positive results from the pivotal Phase III THRIVE trial in active TED and the THRIVE-2 trial in chronic TED.
• The Graves’ ophthalmopathy pipeline continues to expand, reflecting growing interest in novel targeted therapies. Several investigational candidates are advancing through clinical development, including elegrobart from Viridian Therapeutics, satralizumab from Roche, linsitinib from Sling Therapeutics, and others, highlighting an increasingly competitive therapeutic landscape.

Graves Ophthalmopathy Competitive Landscape

Some of the Graves ophthalmopathy drugs under development include Elegrobart (VRDN-003) (Viridian Therapeutics), Linsitinib (Sling Therapeutics), AMG 732 (Amgen), Lonigutamab (Alumis), ENSPRYNG (satralizumab, RG6168) (Roche), and others.

Viridian Therapeutics’ Elegrobart is an investigational monoclonal antibody being developed by Viridian Therapeutics for the treatment of thyroid eye disease. The therapy is designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a well-established driver of TED pathogenesis. Viridian is advancing Elegrobart as a potential best-in-class subcutaneous anti-IGF-1R treatment that can be self-administered at home using a low-volume autoinjector, with dosing intervals of either once every four weeks or once every eight weeks. According to the company’s SEC filing, a Biologics License Application (BLA) submission is expected in the first quarter of 2027.

Sling Therapeutics’ Linsitinib is an investigational oral therapy being developed to reduce the treatment burden associated with TED for patients, caregivers, and healthcare providers. It is the first and only oral small-molecule candidate to demonstrate both statistically and clinically meaningful efficacy in TED. The drug exerts its therapeutic effect by blocking IGF-1R, the only clinically validated target in TED and the mechanism underlying currently approved FDA therapies for the disease. Since activation of IGF-1R contributes to inflammation and the development of proptosis, inhibiting this pathway may help alleviate key manifestations of TED. Linsitinib also has an extensive clinical safety record, having been evaluated in more than 900 patients across 15 clinical studies spanning multiple disease indications.

Amgen’s AMG 732 is a monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R) and is currently under investigation as a potential treatment for thyroid eye disease.

Alumis’ Lonigutamab is a next-generation, humanized IgG1 monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R) and has been developed for subcutaneous administration. In contrast to other IGF-1R-targeting therapies, it recognizes a unique receptor epitope, promoting rapid internalization and degradation of the IGF-1R complex. Its subcutaneous formulation supports more convenient long-term treatment and may improve the depth and durability of clinical responses in patients with chronic conditions. As the first subcutaneous anti-IGF-1R therapy to demonstrate efficacy in thyroid eye disease comparable to intravenously administered therapies, lonigutamab has the potential to combine the proven effectiveness of IGF-1R inhibition with a convenient dosing regimen and a potentially best-in-class safety profile. Alumis is also evaluating strategic alternatives for the future development and commercialization of the lonigutamab program.

The anticipated launch of these emerging therapies are poised to transform the Graves ophthalmopathy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Graves ophthalmopathy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about which pharmaceutical companies are leading in thyroid eye disease @ Graves Ophthalmopathy Drugs

Recent Developments in the Graves Ophthalmopathy Market

• In June 2026, Viridian Therapeutics announced that the FDA had granted approval to LUMVOA (veligrotug-vvze) for the treatment of thyroid eye disease (TED).
• In June 2026, Genentech announced that the FDA had accepted for review and granted priority review status to its supplemental Biologics License Application (sBLA) for ENSPRYNG (satralizumab) as a potential treatment for thyroid eye disease (TED).
• In June 2026, Ethyreal Bio emerged from stealth with USD 101 million in total funding backed by prominent healthcare investors. Its Series A financing was co-led by Atlas Venture and Medicxi Ventures, with participation from Nandi Life Sciences and Checkpoint Capital, while the Series B round was led by Avoro Capital and included all existing Series A investors.
• In March 2026, Viridian Therapeutics announced positive topline data from the elegrobart REVEAL-1 phase III clinical trial in patients with active thyroid eye disease (TED). REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) and Complete resolution of diplopia in 51% of patients treated Q4W versus 16% placebo at week 24.

Graves Ophthalmopathy Epidemiology Segmentation

The Graves ophthalmopathy epidemiology section provides insights into the historical and current Graves ophthalmopathy patient pool and forecasted trends for the leading markets. In 2025, the United States accounted for approximately 1.03 million diagnosed prevalent cases of Graves’ ophthalmopathy, representing the highest disease burden among major markets, followed by the EU4 and the UK, and Japan.

The Graves ophthalmopathy treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Prevalent Cases of Graves Ophthalmopathy 
• Diagnosed Prevalent Cases of Graves Ophthalmopathy
• Gender-specific Prevalent Cases of Graves Ophthalmopathy
• Diagnosed Prevalent Cases of Graves Ophthalmopathy by Chronicity 
• Acute Diagnosed Prevalent Cases of Graves Ophthalmopathy by Severity
• Acute moderate-to-Severe Drug-treated Cases of Graves Ophthalmopathy

Scope of the Graves Ophthalmopathy Market Report

• Graves Ophthalmopathy Patient Population Forecast
• Graves Ophthalmopathy Therapeutics Market Size
• Graves Ophthalmopathy Pipeline Analysis
• Graves Ophthalmopathy Market Size and Trends
• Graves Ophthalmopathy Market Opportunity
• Graves Ophthalmopathy Market Unmet Needs
• KOL’s Views on Graves Ophthalmopathy
• Graves Ophthalmopathy Market Access and Reimbursement

Download the report to understand what drugs are in development for thyroid eye disease @ Graves Ophthalmopathy Clinical Trials

Table of Contents

Related Reports

Graves Ophthalmopathy Clinical Trial Analysis

Graves Ophthalmopathy Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Graves ophthalmopathy companies, including Innovent Biologics (Suzhou) Co. Ltd., Viridian Therapeutics, Inc., ACELYRIN Inc., Kriya Therapeutics, Tourmaline Bio, Inc., Sinocelltech Ltd., Hoffmann-La Roche, Immunovant Sciences GmbH, H. Lundbeck A/S, Sling Therapeutics, Inc., Lassen Therapeutics Inc., Changchun GeneScience Pharmaceutical Co., Ltd., argenx, Amgen, Minghui Pharmaceutical (Shanghai), and others.

Graves’ Disease Market

Graves’ Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Graves’ disease companies, including Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma, Roivant Sciences, Viridian Therapeutics, argenx, Hoffmann-La Roche, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, Alumis (ACELYRIN), and others.

Graves’ Disease Clinical Trial Analysis

Graves’ Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Graves’ disease companies, including Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma, Roivant Sciences, Viridian Therapeutics, argenx, Hoffmann-La Roche, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, Alumis (ACELYRIN), and others.

Hashimoto’s Thyroiditis Market

Hashimoto’s Thyroiditis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Hashimoto’s thyroiditis companies, including TNF Pharmaceuticals, AbbVie, Pfizer, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

info@delveinsight.com

+14699457679

www.delveinsight.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/graves-ophthalmopathy-market-expected-to-witness-rapid-expansion-at-a-cagr-of-9-during-the-forecast-period-20262036-driven-by-the-recent-approval-of-viridians-lumvoa-and-the-launch-of-emerging-therapies–delveinsight-302837401.html

SOURCE DelveInsight Business Research, LLP